DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0105159 A1 Mccleary Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0105159 A1 Mccleary Et Al US 200301 05159A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0105159 A1 McCleary et al. (43) Pub. Date: Jun. 5, 2003 (54) KAVALACTONE COMPOSITIONS AND Publication Classification METHODS OF USE (51) Int. Cl." ....................... A61K 31/35; A61K 31/366; (76) Inventors: Joel McCleary, The Plains, VA (US); A61K 35/78; A61K 31/16 Peter S. Staats, Towson, MD (US) (52) U.S. Cl. ........................... 514/460; 514/625; 424/760 Correspondence Address: FISH & RICHARDSON PC 225 FRANKLIN ST BOSTON, MA 02110 (US) (57) ABSTRACT (21) Appl. No.: 10/214,624 (22) Filed: Aug. 8, 2002 This invention relates tO kavalactone-containing composi tions, and more particularly to compositions having com Related U.S. Application Data pounds derived from kavalactones and from capsaicinoids. The compositions are useful in modulating pain, and thus (60) Provisional application No. 60/311,437, filed on Aug. can be used to mediate, or eliminate, Sensations of pain, 10, 2001. thereby providing pain relief and reduction. US 2003/0105159 A1 Jun. 5, 2003 KAVALACTONE COMPOSITIONS AND METHODS 0006. In one embodiment, the invention relates to an OF USE analgesic topical composition having: (a) a kavalactone; (b) capsaicinoid or Synthetic derivatives thereof; and (c) a CROSS-REFERENCE TO RELATED pharmaceutically acceptable carrier; wherein the weight APPLICATIONS ratio of(a):(b) is from 5000:1 to 1:2 (e.g., 800:1 to 1:1; 500:1 to 5:1). In other aspects, the composition includes an effec 0001. This application claims benefit of U.S. application tive amount of kavalactones, active kavalactones, or capsai Ser. No. 60/311,437, filed, Aug. 10, 2001, which is herein cinoids. In other aspects, the compositions can include one incorporated by reference in its entirety. or more kavalactones or active kavalactones, or one or more capsaicinoids. BACKGROUND 0007. In another embodiment, the compositions herein 0002 Oceania (i.e., the Pacific island communities of can have a kavalactone (e.g., one or more kavalactones, one Micronesia, Melanesia and Polynesia) is an area where kava or more active kavalactones) in about 1-50% (alternatively roots have been highly regarded by native medicine men for about 1-10%, alternatively about 10-20%, alternatively its ability to reduce anxiety and StreSS. In recent years, the about 20-30%, alternatively about 30-40%, alternatively Kava plant has been Scientifically Scrutinized, with certain about 40-50%), by weight and a capsaicinoid or its synthetic of its active constituents being identified. The psychoactive derivative (e.g., one or more capsaicinoids or derivatives ingredients of the Kava root have been identified as kava thereof) in about 0.001-4% (alternatively about 0.001 lactones. A total of Sixteenkavalactones have been identified 0.01%, alternatively about 0.01-0.1%, alternatively about to date, including kawain, dihydrokawain (a.k.a. marindi 0.1-0.5%, alternatively about 0.5-1%, alternatively about nin), methysticin, dihydromethysticin, yangonin, and des 1-2%, alternatively about 2-3%, alternatively about 3-4%), methoxyyangonin. These compounds are neutral, nitrogen by weight. poor compounds that may be specifically referred to as Substituted alpha.-pyrones. The lactone ring is Substituted by 0008. In another embodiment, the composition are any of a methoxy group in the C-4 position, and the compounds those herein wherein the topical composition includes a vary in their Substitution by either a styryl residue (e.g., kavalactone in about 5-20% by weight and a capsaicinoid or yangonin, desmethy-oxyyangonin, kawain, and methysticin) its synthetic derivative in about 0.01-2%, by weight; those or by a phenylethyl residue (e.g., dihydrokawain and dihy wherein the capsaicinoid is 8-methy-N-Vanillyl-6-nonena dromethysticin) at the C-6 position. mide, 8-methyl-N-Vanillyl-nonamide, or a combination thereof; those wherein the capsaicinoid is N-Vanillyl-9- 0003. The particular kavalactones in a Kava root extract octadecenamide; those wherein the kavalactone is an active vary depending upon its origin. The concentration ranges of kavalactone Selected from kawain, dihydrokawain, dihy total kavalactone levels in the Kava root extracts employed, dromethysticin, methysticin, yangonin, desmethoxyyango e.g., in the US are generally within the range of 10 to 30 wt nin, or a combination thereof; those wherein the kavalactone %. Kava root extract is widely available in the world as an includes Synthetic active kavalactone; and those wherein the herbal Supplement in the form of tablets, capsules, and capsaicinoid includes Synthetic capsaicinoid. dragees made of pharmaceutical grade extract. The Kava root extract lactones provide an anxiolytic effect, relieving 0009. The invention also includes a patch including any nervous anxiety, tension, and restleSSneSS, with their efficacy of the compositions herein. One embodiment is a patch as a relaxant having been demonstrated in clinical Studies. including a composition-containing material layer, wherein The kavalactones also effect muscle relaxation. the composition includes a kavalactone and a capsaicinoid or synthetic derivatives thereof; and the patch wherein the 0004 Capsaicin, a substance from the Solanaceae family, kavalactone is an active kavalactone and the capsaicinoid is is known to be effective in mediating pain. Capsaicin is 8-methy-N-Vanillyl-6-nonenamide, 8-methyl-N-Vanillyl known to desensitize nociceptors and various clinical trials nonamide, or a combination thereof. have investigated its analgesic effects. It is known to be an effective agent for pain relief and has been utilized to relieve 0010. The invention also relates to a method for provid various types of pain, including musculoskeletal pain and ing analgesia in a Subject (e.g., humans, animals, mammals) neuropathic pain for example. Capsaicin, however, is also inclduing administering concurrently to the Subject in need known to cause Sensations of burning pain, Sensation of of Such treatment an effective amount of any of the com heat, and hyperalgesia distinct from the neuropathic pain for positions herein, including those having: (a) a kavalactone; which relief is Sought. AS Such, patient compliance is low in (b) a capsaicinoid or Synthetic derivatives thereof, and (c) a treatment protocols using capsaicin. It is thus desirable to pharmaceutically acceptable carrier; wherein the weight develop ways in which the irritation, discomfort, and burn ratio of (a):(b) is from about 5000:1 to about 1:2; those ing pain of the capsaicin can be modulated, while leaving wherein the kavalactone is an active kavalactone Selected unaffected, the capsaicin's beneficial effect on pain relief. from kawain, dihydrokawain, dihydromethysticin, methyS ticin, yangonin, desmethoxyyangonin, or a combination SUMMARY thereof; those wherein the weight ratio of (a): (b) is from about 800:1 to about 1:1; those wherein the weight ratio of 0005. This invention relates to kavalactone-containing (a): (b) is from about 500:1 to about 5:1; those wherein the compositions, and more particularly to compositions having topical composition includes a kavalactone in about 1-50%, compounds derived from kavalactones and from capsaici by weight and a capsaicinoid or its Synthetic derivative in noids. The compositions are useful in modulating pain, and about 0.001-4% by weight; those wherein the topical com thus can be used to mediate, or eliminate, Sensations of pain, position includes a kavalactone in about 5-20% by weight thereby providing pain relief and reduction. and a capsaicinoid or its Synthetic derivative in about US 2003/0105159 A1 Jun. 5, 2003 0.01-2%, by weight; those wherein the capsaicinoid is DETAILED DESCRIPTION 8-methy-N-Vanillyl-6-nonenamide, 8-methyl-N-Vanillyl nonamide, or a combination thereof; those wherein the 0016. In one aspect, the invention relates to a medicinal capsaicinoid is N-Vanillyl-9-octadecenamide. ointment including 1-50% (e.g., about 1-10%, about 10-20%, about 20-30%, about 30-40%, about 40-50%) by 0.011 The invention also relates to a method for amelio weight kavalactone, (e.g., active kavalactone that is kawain, rating the irritation associated with a capsaicinoid including dihydrokawain, dihydromethysticin, methysticin, yangonin, Simultaneous topical administration of a kavalactone and a deSmethoxyyangonin, or a combination thereof), about capsaicinoid; and Such methods wherein the capsaicinoid is 0.001-4% (e.g., about 0.001-0.01%, about 0.01-0.1%, about administered to a Subject for modulating pain. The methods 0.1-0.5%, about 0.5-1%, about 1-2%, about 2-3%, about herein can be those including administration of a topical 3-4%) capsaicinoid, and a pharmaceutically acceptable car composition comprising a kavalactone in about 1-50%, by rier. A kavalactone is any lactone-containing compound weight and a capsaicinoid or its Synthetic derivative in about derived from the kava kava root. The term “active kavalac 0.001-4% by weight, to a subject. tone' herein referS only to kawain, dihydrokawain, dihy 0012. The invention also relates to a method for amelio dromethysticin, methysticin, yangonin, desmethoxyyango rating primary and Secondary hyperalgesia associated with nin, or a combination of them. The amount of kavalactone capsaicin including Simultaneous topical administration of a or active kavalactone can be an effective amount of com kavalactone and a capsaicinoid; a method for treating intrac pound to produce the desired effect (e.g., mediation of table myofacial pain (or Symptoms thereof) including topical irritation, or burning Sensation of capsaicin). administration of any composition herein to a Subject; a 0017 Capsaicinoids are compounds derived from an method for treating osteoarthritis pain (or Symptoms thereof) extract of a capsicum from the Solanaceae family, including including topical administration of a composition of any Capsicum frutescenS Linne and Capsicum annum Linne, and composition herein to a Subject; a method for treating chemical derivatives thereof. In one embodiment, the cap neuropathic pain (or Symptoms thereof) including topical Saicinoids are compounds derived from an extract of a administration of any composition herein to a Subject.
Load more

Recommended publications
  • Plant-Based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies with Supporting Preclinical Evidence
    CNS Drugs 2013; 24 (5) Review Article Running Header: Plant-Based Anxiolytic Psychopharmacology Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence Jerome Sarris,1,2 Erica McIntyre3 and David A. Camfield2 1 Department of Psychiatry, Faculty of Medicine, University of Melbourne, Richmond, VIC, Australia 2 The Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia 3 School of Psychology, Charles Sturt University, Wagga Wagga, NSW, Australia Correspondence: Jerome Sarris, Department of Psychiatry and The Melbourne Clinic, University of Melbourne, 2 Salisbury Street, Richmond, VIC 3121, Australia. Email: [email protected], Acknowledgements Dr Jerome Sarris is funded by an Australian National Health & Medical Research Council fellowship (NHMRC funding ID 628875), in a strategic partnership with The University of Melbourne, The Centre for Human Psychopharmacology at the Swinburne University of Technology. Jerome Sarris, Erica McIntyre and David A. Camfield have no conflicts of interest that are directly relevant to the content of this article. 1 Abstract Research in the area of herbal psychopharmacology has revealed a variety of promising medicines that may provide benefit in the treatment of general anxiety and specific anxiety disorders. However, a comprehensive review of plant-based anxiolytics has been absent to date. Thus, our aim was to provide a comprehensive narrative review of plant-based medicines that have clinical and/or preclinical evidence of anxiolytic activity. We present the article in two parts. In part one, we reviewed herbal medicines for which only preclinical investigations for anxiolytic activity have been performed. In this current article (part two), we review herbal medicines for which there have been both preclinical and clinical investigations for anxiolytic activity.
    [Show full text]
  • Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Kava Kava 9000-38-8; 84696-40-2 November 1998 TABLE OF CONTENTS Basis for Nomination Chemical Identification Production Information Use Pattern Human Exposure Regulatory Status Evidence for Possible Carcinogenic Activity Human Data Animal Data Metabolism Other Biological Effects Structure-Activity Relationships References BASIS OF NOMINATION TO THE CSWG Kava kava is brought to the attention of the CSWG because it is a rapidly growing, highly used dietary supplement introduced into the mainstream U.S. market relatively recently. Through this use, millions of consumers using antianxiety preparations are potentially exposed to kava kava. A traditional beverage of various Pacific Basin countries, kava clearly has psychoactive properties. The effects of its long-term consumption have not been documented adequately; preliminary studies suggest possibly serious organ system effects. The potential carcinogenicity of kava and its principal constituents are unknown. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY The U.S. Pharmacopeia is in the process of reviewing kava kava. No decision on preparation of a monograph has been made. SELECTION STATUS ACTION BY CSWG: 12/14/98 Studies requested: - Toxicological evaluation, to include studies of reproductive toxicity and neurotoxicity - Genotoxicity Priority: High Rationale/Remarks: - Significant human exposure - Leading dietary supplement with rapidly growing use - Concern that kava has been promoted as a substitute for ritilin in children - Test extract standardized to 30 percent kavalactones - NCI is conducting studies in Salmonella typhimurium CHEMICAL IDENTIFICATION CAS Registry Number: 9000-38-8 Kava-kava resin (8CI) Chemical Abstract Service Name: 84696-40-2 CAS Registry Number: Pepper (Piper), P. methysticum, ext. Chemical Abstract Service Name: Extract of kava; kava extract; Piper Synonyms and Trade Names: methisticum extract Description: The tropical shrub Piper methysticum is widely cultivated in the South Pacific.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Sedative
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Sedative Chemical Dosage (+)-BORNYL-ISOVALERATE -- (-)-DICENTRINE LD50=187 1,8-CINEOLE -- 2-METHYLBUT-3-ENE-2-OL -- 6-GINGEROL -- 6-SHOGAOL -- ACYLSPINOSIN -- ADENOSINE -- AKUAMMIDINE -- ALPHA-PINENE -- ALPHA-TERPINEOL -- AMYL-BUTYRATE -- AMYLASE -- ANEMONIN -- ANGELIC-ACID -- ANGELICIN ED=20-80 ANISATIN 0.03 mg/kg ANNOMONTINE -- APIGENIN 30-100 mg/kg ARECOLINE 1 mg/kg ASARONE -- ASCARIDOLE -- ATHEROSPERMINE -- BAICALIN -- BALDRINAL -- BENZALDEHYDE -- BENZYL-ALCOHOL -- Chemical Dosage BERBERASTINE -- BERBERINE -- BERGENIN -- BETA-AMYRIN-PALMITATE -- BETA-EUDESMOL -- BETA-PHENYLETHANOL -- BETA-RESERCYCLIC-ACID -- BORNEOL -- BORNYL-ACETATE -- BOSWELLIC-ACID 20-55 mg/kg ipr rat BRAHMINOSIDE -- BRAHMOSIDE -- BULBOCAPNINE -- BUTYL-PHTHALIDE -- CAFFEIC-ACID 500 mg CANNABIDIOLIC-ACID -- CANNABINOL ED=200 CARPACIN -- CARVONE -- CARYOPHYLLENE -- CHELIDONINE -- CHIKUSETSUSAPONIN -- CINNAMALDEHYDE -- CITRAL ED 1-32 mg/kg CITRAL 1 mg/kg CITRONELLAL ED=1 mg/kg CITRONELLOL -- 2 Chemical Dosage CODEINE -- COLUBRIN -- COLUBRINOSIDE -- CORYDINE -- CORYNANTHEINE -- COUMARIN -- CRYOGENINE -- CRYPTOCARYALACTONE 250 mg/kg CUMINALDEHYDE -- CUSSONOSIDE-A -- CYCLOSTACHINE-A -- DAIGREMONTIANIN -- DELTA-9-THC 10 mg/orl/man/day DESERPIDINE -- DESMETHOXYANGONIN 200 mg/kg ipr DIAZEPAM 40-200 ug/lg/3-4x/day DICENTRINE LD50=187 DIDROVALTRATUM -- DIHYDROKAWAIN -- DIHYDROMETHYSTICIN 60 mg/kg ipr DIHYDROVALTRATE -- DILLAPIOL ED50=1.57 DIMETHOXYALLYLBENZENE -- DIMETHYLVINYLCARBINOL -- DIPENTENE
    [Show full text]
  • Piper Methysticum)
    Journal of Student Research (2015) Volume 4, Issue 2: pp. 69-72 Research Article A Closer Look at the Risks vs. Benefits of Kava (Piper methysticum) Anan A. Husseina If you took a trip to Fiji, the locals would probably welcome you with a drink of Kava. For centuries, the indigenous people of the South Pacific Islands have used the roots of a plant known as Kava. Beyond the use of Kava as a psychoactive substance, it has been incorporated as a cultural drink that is used in many ceremonies. In the late 1990’s Kava use spread quickly in Western countries including Europe, North America, and Australia. It was used as a treatment for anxiety. But just as quickly as it spread, the enthusiasm for it faded, because it was banned or restricted in many Western countries following reports of liver toxicity. In the United States, the Food and Drug Administration’s (FDA) concern for safety prompted a request for more research on the substance. The issues of safety and efficacy remain more specifically whether the benefits of using Kava outweigh the risks. History Kava is a beverage made from the roots of the plant included alcohol, cocaine, tobacco, and heroin. The findings Piper methysticum, and has been used historically in the suggest that kava may reduce the craving associated with the South Pacific Islands as a ceremonial drink. Kava was aforementioned substances, which may make kava a great introduced in Europe around the 1700s by Captain James future candidate to help with addiction. 13 Cook and has since spread widely to Australia, Europe, and Although the mechanism of action is not clear, it is the United States.
    [Show full text]
  • Cover Next Page > Cover Next Page >
    cover next page > Cover title: The Psychopharmacology of Herbal Medicine : Plant Drugs That Alter Mind, Brain, and Behavior author: Spinella, Marcello. publisher: MIT Press isbn10 | asin: 0262692651 print isbn13: 9780262692656 ebook isbn13: 9780585386645 language: English subject Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. publication date: 2001 lcc: RC483.S65 2001eb ddc: 615/.788 subject: Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. cover next page > < previous page page_i next page > Page i The Psychopharmacology of Herbal Medicine < previous page page_i next page > cover next page > Cover title: The Psychopharmacology of Herbal Medicine : Plant Drugs That Alter Mind, Brain, and Behavior author: Spinella, Marcello. publisher: MIT Press isbn10 | asin: 0262692651 print isbn13: 9780262692656 ebook isbn13: 9780585386645 language: English subject Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. publication date: 2001 lcc: RC483.S65 2001eb ddc: 615/.788 subject: Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. cover next page > < previous page page_ii next page > Page ii This page intentionally left blank. < previous page page_ii next page > < previous page page_iii next page > Page iii The Psychopharmacology of Herbal Medicine Plant Drugs That Alter Mind, Brain, and Behavior Marcello Spinella < previous page page_iii next page > < previous page page_iv next page > Page iv © 2001 Massachusetts Institute of Technology All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher. This book was set in Adobe Sabon in QuarkXPress by Asco Typesetters, Hong Kong and was printed and bound in the United States of America.
    [Show full text]
  • Kavain Analogues As Potential Analgesic Agents
    Pharmacological Reports Copyright © 2012 2012, 64, 14191426 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Kavainanaloguesaspotentialanalgesicagents ElaineC.Kormann1,PatriciadeAguiarAmaral2,MicheleDavid3, VeraL.Eifler-Lima4,ValdirCechinelFilho1,FátimadeCamposBuzzi1 1 Chemical-PharmaceuticalInvestigationsCenter(NIQFAR)/CCS,UniversityofItajaíValey(UNIVALI),Itajaí/SC, Brazil 2 LaboratoryofMedicinalPlants(LaPlaM),UniversityoftheExtremeSouthofSantaCatarina(UNESC), Criciúma/SC,Brazil 3 LaboratoryofChemistryTherapeutic(UPRES4090),UniversityofRennes1,Rennes,France 4 LaboratoryofMedicinalOrganicSynthesis(LaSOM),FacultyofPharmacy,FederalUniversityofRioGrande doSul(UFRGS),PortoAlegre/RS,Brazil Correspondence: FátimadeCamposBuzzi,e-mail: [email protected]; VeraL.Eifler-Lima, e-mail: [email protected] Abstract: Background: Kavalactones are pharmacologically active compounds present in preparations of the root trunk of Piper methysticum Forst, known as kava. This work describes the analgesic activity of some synthesized analogues of synthetic kavain, which is the maincomponentofkava. Methods: The essays were initially performed against the writhing test in mice, and the most promising compound was analyzed us- ing other classical models of nociception, including formalin-, capsaicin-, glutamate-induced nociception, the hot plate test, and measurementofmotorperformance. Results: The results indicated that compound 6-(4-fluorophenyl)-4-methoxy-5,6-dihydropyran-2-one (2d) exerts potent and dose- dependent analgesic activity, inhibiting abdominal constrictions caused by acetic acid in mice, and being more active than some ref- erence drugs. It also presented activity in the other models of pain, with the exception of the hot plate test and the measurement of motorperformance. Conclusions: Although compound 2d exerts antinociceptive activity, the mechanism of action remains uncertain, but it does not in- volve the opioid system and does not appear to be associated with non-specific effects such as changes in locomotor activity or motor coordination.
    [Show full text]
  • Acc #: 1131 63 Years FINAL COPY Drug A
    FINAL COPY Patient : DOE, JOHN Acc #: 1131 Birth: 01/01/2001 DOCTOR, TEST Age: 63 years Collection Date: Received in Lab: Drug Adherence Assessment Report CleanAssureTM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: ASPIRIN, BACLOFEN (LIORESAL, GABLOFEN), WARFARIN (COUMADIN), QUETIAPINE (SEROQUEL), OMEPRAZOLE (PRILOSEC, ZEGERID), TOLTERODINE (DETROL), FUROSEMIDE (LASIX), VITAMIN B1 (Thiamine), METOPROLOL (LOPRESSOR), FLUTICASONE (FLONASE), VITAMIN D2 (Ergocalciferol), CYCLOBENZAPRINE (FLEXERIL), PAROXETINE (PAXIL, PEXEVA) CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED ANTICIPATED TEST FLAG DETECTION WINDOW PRESCRIPTION POSITIVE(S) OUTCOME WARFARIN (COUMADIN) Warfarin Positive Plasma Half-Life: 20-60 hours QUETIAPINE (SEROQUEL) Quetiapine Negative Plasma Half-Life: 6-7 hours QUETIAPINE (SEROQUEL) Norquetiapine Positive Plasma Half-Life: 7-12 hours FUROSEMIDE (LASIX) Furosemide Positive Plasma Half-Life: 4-10 hours METOPROLOL (LOPRESSOR) Metoprolol Positive Plasma Half-Life: 3-4 hours METOPROLOL (LOPRESSOR) Alpha-hydroxymetoprolol Positive Plasma Half-Life: 3-4 hours PAROXETINE (PAXIL, PEXEVA) Paroxetine Positive Plasma Half-Life: 21 hours INCONSISTENT RESULTS - REPORTED MEDICATION NOT DETECTED (NEITHER PARENT DRUG NOR METABOLITE) REPORTED ANTICIPATED TEST FLAG DETECTION WINDOW PRESCRIPTION POSITIVE(S) OUTCOME BACLOFEN (LIORESAL, GABLOFEN) Baclofen Negative Plasma Half-Life: 3-4 hrs CYCLOBENZAPRINE (FLEXERIL) Cyclobenzaprine Negative Plasma Half-Life: 8-37 hours OMEPRAZOLE
    [Show full text]
  • Ginkgo Biloba Leaf Extract Induces DNA Damage by Inhibiting
    www.nature.com/scientificreports OPEN Ginkgo biloba leaf extract induces DNA damage by inhibiting topoisomerase II activity in human Received: 10 April 2015 Accepted: 02 September 2015 hepatic cells Published: 30 September 2015 Zhuhong Zhang1, *, Si Chen2, *, Hu Mei3, Jiekun Xuan2, Xiaoqing Guo1, Letha Couch2, Vasily N. Dobrovolsky1, Lei Guo2 & Nan Mei1 Ginkgo biloba leaf extract has been shown to increase the incidence in liver tumors in mice in a 2-year bioassay conducted by the National Toxicology Program. In this study, the DNA damaging effects of Ginkgo biloba leaf extract and many of its constituents were evaluated in human hepatic HepG2 cells and the underlying mechanism was determined. A molecular docking study revealed that quercetin, a flavonoid constituent of Ginkgo biloba, showed a higher potential to interact with topoisomerase II (Topo II) than did the other Ginkgo biloba constituents; this in silico prediction was confirmed by using a biochemical assay to study Topo II enzyme inhibition. Moreover, as measured by the Comet assay and the induction of γ-H2A.X, quercetin, followed by keampferol and isorhamnetin, appeared to be the most potent DNA damage inducer in HepG2 cells. In Topo II knockdown cells, DNA damage triggered by Ginkgo biloba leaf extract or quercetin was dramatically decreased, indicating that DNA damage is directly associated with Topo II. DNA damage was also observed when cells were treated with commercially available Ginkgo biloba extract product. Our findings suggest that Ginkgo biloba leaf extract- and quercetin-induced in vitro genotoxicity may be the result of Topo II inhibition. Ginkgo biloba leaves and their extracts have been used to treat a variety of ailments, including memory loss and cognitive disorders, arrhythmias and ischemic heart disease, diabetes, skin infection, cancer, and thromboses1,2.
    [Show full text]
  • Standard Format for AOAC Standard Method Performance Requirement
    1 DRAFT AOAC SMPR 2017.XXX; Version 11.17.2017 2 3 Method Name: Determination of Kavalactones and/or Flavokavains from Kava (Piper 4 methysticum) 5 6 Approved by: Stakeholder Panel on Dietary Supplements (SPDS) 7 8 Intended Use: For quality assurance and compliance to current good manufacturing practices. 9 10 1. Purpose: 11 AOAC SMPRs describe the minimum recommended performance characteristics to be used 12 during the evaluation of a method. The evaluation may be an on-site verification, a single- 13 laboratory validation, or a multi-site collaborative study. SMPRs are written and adopted by 14 AOAC Stakeholder Panels composed of representatives from the industry, regulatory 15 organizations, contract laboratories, test kit manufacturers, and academic institutions. 16 AOAC SMPRs are used by AOAC Expert Review Panels in their evaluation of validation study 17 data for method being considered for Performance Tested Methods or AOAC Official 18 Methods of Analysis, and can be used as acceptance criteria for verification at user 19 laboratories. [Refer to Appendix F: Guidelines for Standard Method Performance 20 Requirements, Official Methods of Analysis of AOAC INTERNATIONAL (2012) 20th Ed., AOAC 21 INTERNATIONAL, Gaithersburg, MD, USA.] 22 23 2. Applicability: 24 Identification and quantitation of the six major kavalactones (desmethoxyyangonin, 25 dihydrokavain, yangonin, kavain, dihydromethysticin, and methysticin) and/or flavokavains 26 A, B, and C (see table 1 for more detailed information on analytes and figure 1 for molecular 27 structures) derived from the underground portions of kava (Piper methysticum) in plant 28 material, dietary ingredients and dietary supplements as listed table 2. Methods will be 29 accepted that identify and quantify either flavokavains and/or kavalactones.
    [Show full text]
  • Kava: a Review of the Safety of Traditional and Recreational Beverage Consumption
    Kava: a review of the safety of traditional and recreational beverage consumption Technical Report Kava: a review of the safety of traditional and recreational beverage consumption Food and Agriculture Organization of the United Nations World Health Organization Rome, 2016 The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) or of the World Health Organization (WHO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these are or have been endorsed or recommended by FAO or WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by FAO and WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall FAO and WHO be liable for damages arising from its use. The views expressed herein are those of the authors and do not necessarily represent those of FAO or WHO.
    [Show full text]
  • Supplementary Material
    Supplementary Material Figure S1. Coomassie bright blue staining of purified protein, SETDB1 (23 kD), Lane 1, 2 and 3 are liquid flow outs 1, 2 and 3 times from the column Table S1. Cell viability percentages of 502 natural compounds against U251 glioma cells Compound Name Cell viability (%) Compound Name Cell viability (%) Emetine 34.46 Bicuculline, (+)- 75.80 Methyllycaconitine citrate 44.15 Butein 76.09 Streptonigrin 49.91 Rauwolscine 76.29 Brefeldin A 49.94 Deltaline 76.93 Harringtonine 50.79 Eburnamonine, (-)- 77.05 Echinomycin 57.97 Salsolinol HBr 77.21 Dehydroandrographolide 58.25 Pseudopelletierin HCl 78.16 Nonactin 60.74 Quinidine HCl 78.87 Vinblastine sulfate 63.91 Rotenone 79.18 Antimycin A1 66.14 Delcorine 79.19 Thapsigargin 66.72 Brucine n-oxide 79.31 Taxol 67.43 Strychnine HCl 79.34 Radicicol 67.80 Rottlerin 79.98 Vincristine sulfate 69.39 Resveratrol 80.08 Phorbol 12-myristate 13-acetate, 4-a - 73.81 Eriodictyol 80.38 Tunicamycin B 74.38 Sterigmatocystin 81.05 Sitosterol, b - 74.46 Arecoline HBr 81.16 Kaempferol 74.61 Emodin 81.39 Anisomycin 75.32 Gramine 81.52 Rosmarinic acid 75.79 Veratridine 81.59 Veratramine 81.71 Condelphine 84.56 Eriocitrin 81.71 Robinetine 84.58 Narasin 82.20 Quassin 84.80 Bavachinin A 82.27 Quercetin 84.86 Actinomycin D 82.39 Diacetylkorseveriline 84.94 Harmaline HCl 82.48 Cotinine, (-)- 85.01 Chrysoeriol 82.67 Chaetomellic acid A 85.07 Lysergol 82.69 Rhamnetine 85.14 Desoxypeganine HCl 83.13 Austricin 85.48 Datiscetin 83.15 Phytosphingosine 85.74 Harmine HCl 83.42 Rifampicin 85.76 Compound Name
    [Show full text]
  • Assessment Report on Piper Methysticum G. Forst., Rhizoma Final
    21 November 2017 EMA/HMPC/450589/2016 Committee on Herbal Medicinal Products (HMPC) Assessment report on Piper methysticum G. Forst., rhizoma Final Based on Article 10a of Directive 2001/83/EC (well-established use) Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC (traditional use) Herbal substance(s) (binomial scientific name of the plant, including plant part) Piper methysticum G. Forst., rhizoma Herbal preparation(s) Not applicable Pharmaceutical form(s) Not applicable Rapporteur C. Purdel Peer-reviewer O. Palomino 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ................................................................................................................... 2 1. Introduction ....................................................................................................................... 4 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4 1.2. Search and assessment methodology ..................................................................... 7 2. Data on medicinal use ........................................................................................................ 8 2.1. Information about products on the market .............................................................
    [Show full text]